

List of Exhibits with Paragraph Citations

Exhibit Name Number	Citation (Para. Nos.)	Exhibit Description
'131 Patent 1001	1, 31-38, 40-45, 68, 69, 71, 74, 76, 77, 80, 84, 86, 92, 137, 145, 168, 240, 241, 242, 252, 255, 258-260, 281-283	U.S. Patent No. 8,410,131 ("the '131 patent")
Wasik 1002	60, 105, 111, 195-217, 225, 227, 228, 236, 237, 239, 243-257, 261-266, 268-276, 278, 279	PCT Published Application No. WO 01/51049 A1, <i>O-Methylated Rapamycin Derivatives for Alleviation and Inhibition of Lymphoproliferative Disorders</i> , to Wasik et al. ("Wasik")
Navarro 1003	109, 218-224, 226, 227, 232-234, 237, 266, 267, 270-274, 279, 280, 300-303, 307	PCT Published Application No. WO 00/33878 A2, <i>Macrolides</i> , to Navarro et al. ("Navarro")
Crowe 1004	30, 120, 158-162, 228, 230, 231, 234, 235, 237, 274, 276, 278-280, 291, 292, 296-298, 302, 303, 305, 307	Crowe et al., <i>Absorption and Intestinal Metabolism of SDZ-RAD and Rapamycin in Rats</i> , Drug Metab. Disp. (1999), 27(5): 627-632 ("Crowe")
Luan 1005	100, 190-192, 194, 228, 235, 237, 274, 276-279, 303, 304, 306, 307	Luan et al., <i>Sirolimus Prevents Tumor Progression: mTOR Targeting for the Inhibition of Neoplastic Progression</i> , Am. J. Transplant. (2001) 1 Suppl 1, 243 (Abstr. No. 428) ("Luan")
Hidalgo 1006	98, 116, 120, 178-189, 229, 230, 234, 235, 237, 280, 284-287, 290, 291, 293, 295, 297, 298, 302, 303, 306, 307,	Hidalgo et al., <i>The Rapamycin-sensitive Signal Transduction Pathway as a Target for Cancer Therapy</i> , Oncogene (2000) 19(56): 6680-6686 ("Hidalgo")
Alexandre 1007	114, 115, 172-177, 229, 230, 234, 235, 237, 280, 288-291, 295, 297-298, 302, 303, 307	Alexandre et al., <i>CCI-779, A new Rapamycin Analog, Has Antitumor Activity at Doses Including Only Mild Cutaneous Effects and Mucositis: Early Results of an Ongoing Phase I Study</i> , Clin. Cancer Res. Suppl. (1999) 5: 3730s, Abstr. No. 7 (AACR-NCI-

List of Exhibits with Paragraph Citations

Exhibit Name Number	Citation (Para. Nos.)	Exhibit Description
		EORTC International Conference, November 16-19, 1999 held in Washington, DC) ("Alexandre")
Schuler 1008	26, 29, 30, 104, 110, 119, 120, 149-157, 160, 185, 198, 228, 230, 231, 234, 235, 237, 276, 280, 291, 292, 296-298, 302, 303, 305, 307	Schuler et al., <i>SDZ RAD, A New Rapamycin Derivative</i> , <i>Transplantation</i> (1997) 64(1): 36-42 ("Schuler")
Neumayer 1009	106, 163-171, 232-234, 237, 280, 294, 297-299, 301-303, 307	Neumayer et al., <i>Entry-into-human Study with the Novel Immunosuppressant SDZ RAD in Stable Renal Transplant Patients</i> , <i>Br. J. Clin. Pharmacol.</i> (1999) 48(5): 694-703 ("Neumayer")
Pantuck Declaration 1010	N/A	Declaration of Allan J. Pantuck, M.D. in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent No. 8,410,131
2015 Orange Book 1029	23 (n. 2), 109 (n. 5)	2015 Orange Book, "35 th Edition (2015) with respect to AFINITOR [®] " ("2015 Orange Book")
'714 PCT Application 1014	16	International Patent Application No. PCT/EP02/01714 ("the '714 PCT Application")
AFINITOR [®] Apr 26, 2012 approval 1107	142	AFINITOR [®] approval letter and prescribing information, as of April 26, 2012 ("AFINITOR [®] Apr 26, 2012 approval")
AFINITOR [®] Jun 14, 2016 prescribing information 1071	107	AFINITOR [®] prescribing information, as of June 14, 2016 ("AFINITOR [®] Jun 14, 2016 prescribing information")
AFINITOR [®] Mar 30, 2009 approval 1070	107, 140	AFINITOR [®] approval letter and prescribing information, as of March 30, 2009 ("AFINITOR [®] Mar 30, 2009 approval")

List of Exhibits with Paragraph Citations

Exhibit Name Number	Citation (Para. Nos.)	Exhibit Description
Alexandre and Raymond 1030	25, 27, 29, 113	Alexandre, Raymond, <i>et al.</i> , <i>La rapamycine et le CCI-779</i> , Bull. Cancer (1999) 86(10): 808-811 ("Alexandre and Raymond")
Bahnson 1044	88, 123, 127, 128, 130, 132,	Robert R. Bahnson, <i>Renal and Urinary Tract Neoplasia</i> (371-379), In Primer on Kidney Diseases (Greenberg, A. et al. eds., 2nd ed. 1998) ("Bahnson")
Baker 1047	95	Baker et al., <i>Rapamycin (AY-22,989), A New Antifungal Antibiotic III. In Vitro and In Vivo Evaluation</i> , J. Antibiotics (1978) 31(6): 539-545 ("Baker")
Beuvink 1077	111	Beuvink et al., <i>Antitumor Activity of RAD001, an Orally Active Rapamycin Derivative</i> , Proc. Amer. Assoc. Cancer Res. (2001) 42, 366, Abstr. No. 1972 ("Beuvink")
Bissler 1109	141	Bissler et al., <i>Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangiomyomatosis</i> , New Engl. Journal Med. (2008) 358(2): 140-151 ("Bissler")
Boni 1031	29, 114, 119	Boni et al., <i>Pharmacokinetics of escalating doses of CCI-779 in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Solid Tumors</i> , Eur. J. Cancer (2001) 37(Suppl. 6): S68 (Abstr. No. 242) (The 11 th ECCO October 21-25, 2001 meeting held in Lisbon, Portugal) ("Boni")
Breitenbach 1060	100	Breitenbach et al., <i>Rapamycin Inhibits Tumor Growth and Metastasis in Mice by Antiangiogenesis</i> , Am. J. Transplant. (2001) 1 Suppl 1, 250 (Abstr. No. 459) ("Breitenbach")
Calne 1053	97	Calne et al., <i>Rapamycin for Immunosuppression in Organ Allografting</i> , Lancet (1989) 2(8656): 227 ("Calne")
Cantley 1097	122, 122 (n. 8), 184 (n. 14), 186	Cantley et al., <i>New Insights into Tumor Suppression: PTEN suppresses Tumor Formation by restraining the Phosphoinositide 3-Kinase / AKT Pathway</i> , Proc. Natl. Acad. Sci. USA, (1999) 96 (8): 4240-4245 ("Cantley")
Caufield '670 patent	102, 155 (n. 9)	U.S. Patent No. 5,221,670 to Caufield ("Caufield '670 patent")

List of Exhibits with Paragraph Citations

Exhibit Name Number	Citation (Para. Nos.)	Exhibit Description
1066		
Choi 1057	98	Choi et al., <i>Structure of the FKBP12-Rapamycin Complex Interacting with the Binding Domain of Human FRAP</i> , Science (1996) 273(5272): 239-242 ("Choi")
Choueiri 1105	141	Choueiri et al., <i>Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma</i> , New England Journal Med. (2015) 373(19): 1814-1823 ("Choueiri")
Cottens '772 patent 1019	23, 26, 27, 28, 32, 47, 99, 100, 102, 103, 110, 198	U.S. Patent No. 5,665,772 to Cottens et al. ("Cottens '772 patent")
Cottens WO '010 1026	47, 53, 54, 58, 59, 103, 110, 198, 211, 217, 223, 247	Published Application No. WO 94/09010 A1, <i>O-Alkylated Rapamycin Derivatives and their use, particularly as immunosuppressants</i> , to Cottens et al. ("Cottens WO '010")
Cowan 1090	120	Cowan et al., <i>Sirolimus: Mammalian Target of Rapamycin Inhibitor to Prevent Kidney Rejection</i> , Nephrol. Nursing Journal (2000) 27(6): 623-625 ("Cowan")
Dancey 1016	98, 120	Dancey, J. E., <i>Rapamycin-Sensitive Signal-Transduction Pathways: Protein Translation Control of Cell Proliferation</i> , ASCO Educational Book (2000) 68-75 ("Dancey")
DeMario 1084	115	DeMario et al., <i>Oral Chemotherapy: Rationale and Future Directions</i> , J. Clin. Oncol. (1998) 16(7): 2557-2567 ("DeMario")
Dinney 1032	39, 123, 126, 136, 138, 214 (n. 16), 244 (n. 21)	Dinney et al., <i>Biology of Metastasis: Studies in Renal Cancer</i> (17-24), in Principles and Practice of Genitourinary Oncology (Raghavan et al. eds., 1997) ("Dinney")
Dukart WO '000 1036	61, 62, 63	PCT Published Application No. WO 02/40000 A2, <i>Use of CCI-779 as an Antineoplastic Agent</i> , to Dukart et al. ("Dukart WO '000")
Dukart '137 1039	63	U.S. Patent Application Publication No. 2002/0091137 A1, <i>Use of CCI-779 as an Antineoplastic Agent</i> , which published on July 11, 2002, to Dukart ("Dukart '137")
Dukart Dukart '446	63 and 63 (n. 3)	U.S. Patent No. 7,781,446, <i>Use of CCI-779 as an Antineoplastic Agent</i> , which issued to Dukart et al. on August 24, 2010 ("Dukart

List of Exhibits with Paragraph Citations

Exhibit Name Number	Citation (Para. Nos.)	Exhibit Description
Dukart Provisional 1040		'446"), and which claims priority to U.S. Provisional Patent Application No. 60/249,077 ("Dukart Provisional")
Dukart WO '416 1038	61, 62, 63	PCT Published Application No. WO 02/098416 A2, <i>Antineoplastic Combinations</i> , to Dukart et al. ("Dukart WO '416")
Dukart '923 1024	63	U.S. Patent Application Publication No. 2003/0008923 A1, <i>Antineoplastic Combinations</i> , which published on January 9, 2003 from an application filed on June 1, 2001 to Dukart ("Dukart US '923")
Eng 1050	96, 100	Eng et al., <i>Activity of Rapamycin (AY-22,989) against Transplanted Tumors</i> , J. Antibiotics (1984) 37(10): 1231-1237 ("Eng")
Escudier 1106	141	R. J. Motzer, B. Escudier et al., <i>Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma</i> , New England Journal Med. (2015) 373(19): 1803-1813 ("Escudier")
Everolimus INN 1074	110	International Nonproprietary Names of Pharmaceutical Substances (INN), WHO Drug Information, (2000) 14(3): 183-209 ("Everolimus INN")
Flowchart 1025	63	Flowcharts for 35 U.S.C. § 102(e) Dates ("102(e) Date Flowchart")
Fosså 1034	53, 55	Fosså et al., <i>Survival of Patients with Advanced Urothelial Cancer treated with Cisplatin-based Chemotherapy</i> , Brit. J. Cancer (1996) 74: 1655-1659 ("Fosså")
Freireich 1068	105 (n. 4), 202	Freireich et al., <i>Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man</i> , Cancer Chemotherapy Reports (1966) 50(4): 219-244 ("Freireich")
Garber 1059	100	Garber, K., <i>Rapamycin's Resurrection: A New Way to Target the Cancer Cell Cycle</i> , J Natl Cancer Inst. (2001) 93(2): 1517-1519 ("Garber")
GB '072 priority application (or GB '072) 1012	16, 143, 144, 147	Great Britain patent application (GB 0104072.4, "GB '072" or "the '072 priority application"), filed on February 19, 2001

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.